Punding in Parkinson's disease

Practical Neurology

Volumn 7, Issue 6, 2007, Pages 397-399

  O'Sullivan, Sean S ^a   Evans, Andrew H ^b   Lees, Andrew J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CABERGOLINE; COCARELDOPA; ENTACAPONE; HYPNOTIC AGENT; QUETIAPINE; UNCLASSIFIED DRUG;

ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR DISORDER; CLINICAL FEATURE; DISEASE ASSOCIATION; EVENING DOSAGE; HUMAN; LOW DRUG DOSE; MANIA; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PUNDING BEHAVIOR; SLEEP DEPRIVATION;

ADULT; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE; DOPAMINE AGONISTS; HUMANS; IMPULSIVE BEHAVIOR; MALE; MENTAL DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; PARKINSON DISEASE;

EID: 36949035763     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2007.129015     Document Type: Article

References (8)

1. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
2. Rylander G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir 1972;75:203-12.
3. Schiorring E. Psychopathology induced by "speed drugs". Pharmacol Biochem Behav 1981;14(Suppl1): 09-22.
4. Friedman JH. Funding on levodopa. Biol Psychiatry 1994; 36:350-1.
5. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006;21:524-9.
6. Miwa H, Morita S, Nakanishi I, et al. Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease. Parkinsonism Relat Disord 2004;10:177-80.
7. Miyasaki JM, Al Hassan K, Lang AE, et al. Punding prevalence in Parkinson's disease. Mov Disord 2007;22:1179-81.
8. Silveira-Moriyama L, Evans AH, Katzenschlager R, et al. Punding and dyskinesias. Mov Disord 2006;21:2214-17.